Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | ABL1 | P00519 | 1/20 | 0.85 |
| ▸ | LMNA | P02545 | 1/20 | 0.85 |
| ▸ | PKM | P14618 | 1/20 | 0.85 |
| ▸ | IDE | P14735 | 1/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.85 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.85 |
| ▸ | HLCS | P50747 | 6/20 | 0.60 |
| ▸ | CA12 | O43570 | 7/20 | 0.50 |
| ▸ | CA1 | P00915 | 7/20 | 0.50 |
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | CA9 | Q16790 | 7/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL3827271 | 0.94 | TDP1 (0.87) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL19988310 | 0.92 | TDP1 (0.94) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL38817 | 0.92 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL8763 | 0.92 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL10047687 | 0.92 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL23055065 | 0.92 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL20547409 | 0.92 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL21981206 | 0.92 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL22943835 | 0.92 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL14489489 | 0.92 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260086095-A1 | METHODS FOR DETECTION OF PROSTATE CANCER, RELATED BIOMARKERS AND KITS FOR DETERMINING THE BIOMARKERS | OY ARCTIC PARTNERS AB (FI) | 2026-03-26 | — | — | US | disclosed |
| EP-4581365-A1 | METHODS FOR DETECTION OF PROSTATE CANCER, RELATED BIOMARKERS AND KITS FOR DETERMINING THE BIOMARKERS | OY Arctic Partners AB (FI) | 2025-07-09 | — | — | EP | disclosed |
| US-20250208144-A1 | ASSAY FOR LONG FORMS OF CARDIAC TROPONIN T | TURUN YLIOPISTO (FI) | 2025-06-26 | — | — | US | disclosed |
| US-20250102510-A1 | LECTIN-BASED DIAGNOSTICS OF CANCERS | UNIOGEN OY (FI) | 2025-03-27 | — | — | US | disclosed |
| EP-4500188-A1 | ASSAY FOR LONG FORMS OF CARDIAC TROPONIN T | Turun yliopisto (FI) | 2025-02-05 | — | — | EP | disclosed |
| US-12196756-B2 | Lectin-based diagnostics of cancers | UNIOGEN OY (FI) | 2025-01-14 | — | — | US | disclosed |
| CN-119137480-A | Assay for long form cardiac troponin T | 图尔库大学 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024047283-A1 | METHODS FOR DETECTION OF PROSTATE CANCER, RELATED BIOMARKERS AND KITS FOR DETERMINING THE BIOMARKERS | OY ARCTIC PARTNERS AB (FI) | 2024-03-07 | — | — | WO | disclosed |
| US-20230393137-A1 | COMPOSITIONS AND METHODS RELATED TO DIAGNOSIS OF PROSTATE CANCER | OPKO DIAGNOSTICS, LLC (US) | 2023-12-07 | — | — | US | disclosed |
| EP-3123381-B1 | COMPOSITIONS AND METHODS RELATED TO DIAGNOSIS OF PROSTATE CANCER | OPKO DIAGNOSTICS LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-6967081-B1 | Method for prediction of bone fractures by osteocalcin measurements | KAEKOENEN SANNA-MARIA | 2005-11-22 | — | — | US | disclosed |
| WO-2005073727-A1 | IMPROVED METHOD FOR DIAGNOSING ACUTE CORONARY SYNDROME | TURUN YLIOPISTO (FI) | 2005-08-11 | — | — | WO | disclosed |
| US-20040259167-A1 | gamma-carboxylated osteocalcin of given sequence, where a specified glutamic acid is gamma-carboxylated; derived from human urine; use to measure rate of bone turnover in metabolic bone disorders | HELLMAN JUKKA (FI) | 2004-12-23 | — | — | US | disclosed |
| EP-1166122-A1 | METHOD FOR PREDICTION OF BONE FRACTURES BY OSTEOCALCIN MEASUREMENTS | Käkonen, Sanna-Maria (FI) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058732-A1 | METHOD FOR PREDICTION OF BONE FRACTURES BY OSTEOCALCIN MEASUREMENTS | KAEKOENEN SANNA MARIA (FI) | 2000-10-05 | — | — | WO | disclosed |
| EP-1003778-A1 | ISOLATED OSTEOCALCIN FRAGMENTS | Hellman, Jukka (FI) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999009058-A1 | ISOLATED OSTEOCALCIN FRAGMENTS | HELLMAN JUKKA (FI) | 1999-02-25 | — | — | WO | disclosed |
| EP-0060700-B1 | ASSAY METHOD AND DEVICE | IMMUNO-MYCOLOGICS, INC. (US) | 1985-11-21 | — | — | EP | disclosed |
| US-4425438-A | Assay method and device | IMMUNO-MYCOLOGICS, INC., A CORP. OF OK. | 1984-01-10 | — | — | US | disclosed |
| EP-0060700-A1 | Assay method and device | IMMUNO-MYCOLOGICS, INC. (US) | 1982-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260086095-A1 | METHODS FOR DETECTION OF PROSTATE CANCER, RELATED BIOMARKERS AND KITS FOR DETERMINING THE BIOMARKERS | LGALS9, KLK3, SIGLEC9 | TDP1 3047/4885MEN1 354/4885ABL1 4795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.